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The prevalence of sarcoidosis in the United States is unknown, with estimates ranging widely
from 1 to 40 per 100,000. We sought to determine the prevalence of sarcoidosis in our health
system compared to other rare lung diseases and to further establish if the prevalence was
changing over time. We interrogated the electronic medical records of all patients treated
in our health system from 1995 to 2010 (1.48 million patients) using the common ICD9 codes
for sarcoidosis (135), lung cancer (162), and several other lung diseases characterized, like
sarcoidosis, as “rare lung diseases”. The patient demographic information (race, gender,
age) was further analyzed to identify signature data patterns. The prevalence of sarcoidosis
in our health system increased steadily from 164/100,000 in 1995 to 330/100,000 in 2010,
and this trend could not be ascribed simply to changes in patient demographics or patient
referral patterns. We further estimate that the prevalence of sarcoidosis exceeds 48 per
100,000 in Franklin County, Ohio, the demographic profile of which is nearly identical to that
of the U.S. Sarcoidosis prevalence increased over time relative to lung cancer, a benchmark
disease with stable disease prevalence, and exceeded that of other rare lung diseases. We
postulate that the observed 2-fold increase in sarcoidosis disease prevalence in our health
system is primarily related to improved detection and diagnostic approaches, and we conclude
that the actual prevalence of sarcoidosis in central Ohio greatly exceeds current U.S. esti-
mates.
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census.gov/qfd/states/39/39049.html), and was uploadedSarcoidosis is a chronic systemic disease, most commonly
affecting the lungs, that afflicts adults in the primes of
their lives. Based upon the ACCESS trial, the largest
epidemiological study on sarcoidosis to date, the annual
incidence of the disease varies from 5/100,000 in whites
to 39/100,000 in African Americans,1 with an overall
prevalence estimated to be 15/100,000 in the USA (www.
orpha.net/orphacom/cahiers/docs/GB/Prevalence_of_rare_
diseases_by_alphabetical_list.pdf). As such, sarcoidosis is
characterized as a “rare lung disease” (i.e., prevalence
<200,000 cases) in the USA. However, firm data relating to
the true prevalence of sarcoidosis is lacking and it is
unclear if the prevalence of disease is changing over time.
Several features of sarcoidosis tend to obscure the
diagnosis, leading to an under-appreciation of the potential
impact of the disease on the health care system and society
as a whole. Sarcoidosis frequently presents with non-
specific complaints, ranging from fatigue and depression,
“asthma symptoms” (wheezing, cough), to arthritis and
muscle pain or weakness. As such, sarcoidosis can mimic
other diseases, leading to misdiagnosis and inappropriate
treatments. When these non-specific disease manifesta-
tions prevail, or when symptoms are absent,2 the under-
lying diagnosis of sarcoidosis may be overlooked. In support
of this concept, a review of 9324 forensic autopsies cases in
Cuyahoga County (Cleveland), Ohio, indicated that 31
exhibited histopathological evidence of sarcoidosis, which
conforms to a population risk of 300/100,000, an order of
magnitude higher than suspected based upon death
certificate reporting.3 While it is not possible from the
information available from these forensic cases to confirm
that all cases were properly classified as sarcoidosis, the
study suggests that the true prevalence of sarcoidosis is
underestimated.
Several recent developments could contribute to an
apparent and/or actual increase in the prevalence of
sarcoidosis over the past 15 years. There is reason to
believe that the detection of sarcoidosis has improved as
clinical standards have shifted toward high-resolution
imaging techniques (e.g., CT scanning) and with the
development of novel sampling techniques [e.g., endo-
bronchial ultrasound-guided biopsy4]. And to the extent
that exposure to various environmental antigens promotes
sarcoidosis,5 it follows that acute or chronic exposures to
inhaled6 and perhaps ingested antigens7 could contribute to
more cases of sarcoidosis. The objective of this study was
to determine if the prevalence of sarcoidosis is changing
over time in our health system and in our community.Methods
Patient population
The Ohio State University Medical Center’s institutional
Information Warehouse (IW) was interrogated from 1995 to
2010 by means of Structured Query Language (SQL) queries.
The census data for Franklin County was obtained from the
US Census Bureau’s online resources (http://quickfacts.into the IW in the form of database tables. The patient
demographic information (race, gender, age) was gathered
for patient groups using specific ICD9 diagnosis codes for
sarcoidosis (135), idiopathic pulmonary fibrosis (IPF; 516.3),
hypersensitivity pneumonitis (HSP, 495), alpha-1 antitrypsin
deficiency (AAT, 273.4), and lung cancer (162); demo-
graphics on all patients within our system were collected as
well. In this regard, The Ohio State University Medical
Center is a regional referral center for all of these rare lung
diseases. For the purposes of these analyses each patient
was counted once for a given year.
Statistical approach
Data were analyzed by using SAS version 9.2. Line plots
were presented to show the trend and the relationship
between variables. Cochran-Armitage8 trend test was used
to analyze the proportional trend in years and association
between variables. Significance was accepted if p  0.05.
Results
Demographics of the regional population
The demographic profile of Columbus, Ohio closely
approximates that of the USA (Table 1; and 2010 census
results: http://quickfacts.census.gov/qfd/states/00000.
html).
Comparison of sarcoidosis prevalence to that of
other rare lung diseases
Ohio State University Medical Center (OSUMC) is a regional
referral center for all types of lung disease, including sub-
specialty clinics for rare lung diseases (IPF, HSP, AAT,
sarcoidosis), as well as lung cancer. A total of 1.48 million
patients were encountered at OSUMC from 1995 to 2010,
and were included in the analysis. The overall disease
prevalence and the number of patient encounters attrib-
uted to the diagnosis of sarcoidosis was significantly higher
than for any of the other rare lung diseases (Table 2).
Given that sarcoidosis prevalence is influenced by race
and gender, we further analyzed the contribution of these
variables in the observed changes in sarcoidosis prevalence
over time within the OSUMC cohort. There was no statisti-
cally significant linear trend in proportion of males and
females within the OSUMC study population or based on the
diagnosis of sarcoidosis (Fig. 2). There was a statistically
significant linear trend in proportion between whites and
African Americans in the study population (Fig. 3A). The
expected increasing trend in proportion of African Ameri-
cans over the 15-year span changes from 18% to 21.4% while
expected decreasing trend in the proportion of whites in
years changes from 81.5% to 78.5%. However, there is no
statistically significant linear trend in proportion of African
American and whites based on the diagnosis of sarcoidosis
(Fig. 3B). There was statistically significant linear trend in
proportion between sarcoidosis and Lung cancer (Fig. 4).
The expected increasing trend in the proportion of
Table 1 Demographics of Columbus, Ohio patient population compared to U.S. in 2010.
Race Gender Age
African American Other White Female Male Median
OSU Health System 14% 12% 74% 52% 48% 49.1
US Census 13% 15% 73% 51% 49% 36.8
Increasing prevalence of sarcoidosis 895sarcoidosis in years from 52.9% to 65.6% while the expected
decreasing trend in the proportion of the lung cancer from
47.1% to 34.3%.
Changes in prevalence of sarcoidosis over time in
our health care system
In keeping with previous reports,1,9 sarcoidosis was most
common in the thirdefifth decades (Fig. 1) with a strong
female gender bias (Fig. 2). With regard to gender, it is
interesting to note that females tend to seek medical
attention more often than males,10 which could influence
the perceived gender distribution. Despite regional census
data indicating that the ratio of African Americans to
whites is w1:5, the absolute number of African Americans
presenting with sarcoidosis slightly exceeded that of whites
(Fig. 3). Over the 15-year period analyzed in this study
there was no significant change in the age distribution,
(Fig. 3). The overall prevalence of sarcoidosis in our patient
population increased steadily from 164/100,000 in 1995 to
330/100,000 in 2010, whereas the prevalence of lung
cancer and the population of Franklin County were
unchanged over time (Fig. 4). This increase in sarcoidosis
prevalence over time remained highly significant after
adjusting for changes in regional referral patterns, based
upon zip code location of residence.
Estimate of sarcoidosis prevalence in Columbus,
Ohio
Limiting the analysis of patient data to residency zip codes
within Columbus, OH; and very conservatively assuming
that all sarcoidosis cases in this referral base were cared for
at our institution, the minimum estimated prevalence of
sarcoidosis in Columbus, OH was 48/100,000 in 2010.The
actual market share of our health care system for the
greater Columbus area ranged from 23% in 1995 to 26% inTable 2 Sarcoidosis prevalence compared to other rare lung di
Sarcoidosis HP
ICD9 Codes 135 495
Prevalence
(patients)
3758 528
Encounters
(visits)
33,281 1333
Age (avg) 49 53
Female
gender
58% 51%
RACE 57%(W)e40%
(B)e3%(O)
83%(W)e13%
(B)e4%(O)2010, which indicates to us that regional sarcoidosis prev-
alence may be as much as 4-fold greater than our conser-
vative estimate. Thus, the true prevalence of sarcoidosis in
this region may exceed 200/100,000 in 2010.
Discussion
The actual health care burden associated with sarcoidosis
in the U.S. is unknown; however, this study suggests that
the prevalence of sarcoidosis and number of hospital
encounters in our patient population is significantly higher
than for other rare lung diseases, and is much greater than
current estimates in the general population.1 Sarcoidosis
prevalence has increased wtwo-fold within the past 15
years in our health system, a finding not fully explained by
changes in the distribution of the patient population with
respect to race or gender or changes in regional referral
patterns. In this regard, the prevalence of sarcoidosis was
shown to increase over time relative to lung cancer, an
index disease for which the national prevalence trends have
remained relatively stable over the past 15 years.11 Using
the most conservative analytical approach, the prevalence
of sarcoidosis in Columbus, Ohio, a population closely
resembling the demographic profile of the U.S., was at least
48/100,000 in 2010, which is over 3-times greater than
estimates of sarcoidosis prevalence in the U.S. reported
the Orphanet Reporter Series for Rare Diseases (www.
orpha.net/orphacom/cahiers/docs/GB/Prevalence_of_rare_
diseases_by_alphabetical_list.pdf), a resource used by the
NIH’s Office of Rare Lung Diseases Research to track disease
prevalence.
Previous studies have indicated that sarcoidosis may be
much more common than currently predicted.3,12e14
Interestingly, a large autopsy series conducted in Cleve-
land, Ohio indicated that the prevalence of sarcoidosis may
be closer to that reported in our health system.3 If our
health system prevalence data (i.e., 330/100,000 in 2010)seases.
IPF AAT Total 1995e2010
516.3 273.4 All
2297 179 1.48 Million
15,523 718 22.96 Million
Encounters
61 52 46
51% 45% 54%
81%(W)e15%
(B)e4%(O)
93%(W)e5%
(B)e2%(O)
74%(W)e14%
(B)e12%(O)
Figure 2 Changes in gender distribution over the years of 1995 and 2010. Panel A: Females are represented in blue and males
in red. Panel B: Comparing genders, there was no statistically significant linear trend in proportions within the sarcoidosis pop-
ulation (pZ 0.45). (For interpretation of the references to color in this figure legend, the reader is referred to the web version of
this article.)
Figure 1 Sarcoidosis age distribution 1995e2010. The average age of the sarcoidosis patients was 48 yrs, with the vast majority
falling in the 3rd (light blue), 4th (dark blue), and 5th (red) decades. (For interpretation of the references to color in this figure
legend, the reader is referred to the web version of this article.)
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Figure 3 Changes in race distribution over the years of 1995 and 2010; overall race distribution. Panel A: African American
(blue) and white (red) race represented the majority of sarcoidosis patients, reflecting regional demographics. Panel B: Comparing
African American and white race, there was no statistically significant linear trend in proportions within the sarcoidosis population
(p Z 0.07). (For interpretation of the references to color in this figure legend, the reader is referred to the web version of this
article.)
Increasing prevalence of sarcoidosis 897were to reflect national trends, it would correspond to over
900,000 sarcoidosis cases in the U.S., placing it well outside
of the range of rare lung diseases. Using an extremely
conservative approach, including the assumption that all
regional sarcoidosis patients are cared for at OSUMC, the
prevalence of sarcoidosis was at least 48/100,000 in the
greater Columbus, Ohio population in 2010. To the extent
that our patient population is representative of trends in
the U.S., the burden of this disease on our health care
system and society as a whole (e.g., disability, missed
work, reduced quality-of-life) may be much higher than
anticipated. The high prevalence of sarcoidosis observed in
our patient population, including comparisons to other rare
lung diseases (Table 2), is in keeping with European studies
indicating that sarcoidosis is much more common than
other interstitial lung diseases.15 Accepting that the annualincidence of sarcoidosis among those of European and
African American decent are estimated to be 3e10/100,000
and 35e80/100,000, respectively,16 and considering that
most patients with sarcoidosis survive greater than 10 years
after the diagnosis,17 it follows that the lifetime risk of
developing sarcoidosis in the U.S. would exceed the annual
incidence by at least an order of magnitude. Our findings
support this simple mathematical model.
There are a number of limitations of this study that
could explain the apparent rapid increase in disease
prevalence in our health system within the past 15 years.
Potential bias includes the availability of more sensitive
diagnostic screening techniques (e.g., CT scan), improved
survival, greater recognition of sarcoidosis among medical
professionals, and changing referral patterns to our
institution. Alternatively, environmental (e.g., antigen
Figure 4 Sarcoidosis prevalence vs. lung cancer prevalence over time. Changes in prevalence of sarcoidosis (Sarcoid; red
triangles) and lung cancer (Lung CA; blue squares) are plotted over time from 1995 to 2000. Note that the trend lines for sarcoidosis
and lung cancer were derived from patients residing in zip codes within Franklin County (Columbus), OH, to reduce bias relating to
changing referral patterns. Trends in Franklin County population change (green triangles) are based upon actual US Census Data
from 1990, 2000 and 2010 as well as the census estimates for intervening years. There was a statistically significant linear trend in
proportion over time for sarcoidosis (p Z 0.0001) from 52.9% (1995) to 65.6% (2010), with no attendant change in Franklin County
population. See text for details. (For interpretation of the references to color in this figure legend, the reader is referred to the
web version of this article.)
898 B.S. Erdal et al.exposure) or host factors (e.g., stress, low vitamin D
levels, a decline in smoking rates) could be contributing
to the recent increase in sarcoidosis prevalence. Despite
all of these potential confounders, it is undeniable that
the regional prevalence of sarcoidosis is at least 48/
100,000, much higher than current estimates (see above).
Beyond the demographic similarities of Franklin County,
Ohio to the U.S., this study does not account for varia-
tions in environmental antigen exposure which could
contribute to higher regional sarcoidosis prevalence.
Further studies are needed to clarify the actual burden of
disease, both regional and national, and to identify the
variables contributing to the apparent increases in
disease prevalence (this study) and mortality.17
In summary, this study demonstrates an unexpectedly
high prevalence of sarcoidosis in a large Midwest U.S.
community, the demographic profile of which closely
matches that of the U.S. The apparent prevalence is rapidly
increasing over the past 15 years. We speculate that
improved screening (e.g., CT scans) and diagnostic tech-
niques, together with increased disease awareness, has
improved our ability to detect disease. However, it remains
possible that the regional prevalence of sarcoidosis has
increased due to changes in host or environmental factors.
Uncertainties relating to disease prevalence, together with
recent data showing that sarcoidosis-related mortality is
increasing over the past several decades in the U.S.,17
emphasize the need to determine the true prevalence of
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